FY2025 EPS Estimates for Dr. Reddy’s Laboratories Limited (NYSE:RDY) Decreased by Zacks Research

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Equities researchers at Zacks Research decreased their FY2025 earnings estimates for shares of Dr. Reddy’s Laboratories in a research report issued to clients and investors on Wednesday, August 14th. Zacks Research analyst R. Department now anticipates that the company will earn $3.99 per share for the year, down from their previous forecast of $4.08. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.13 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q1 2027 earnings at $0.95 EPS and FY2027 earnings at $3.24 EPS.

RDY has been the topic of a number of other reports. Barclays lifted their target price on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. StockNews.com cut Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 16th.

Dr. Reddy’s Laboratories Stock Performance

NYSE RDY traded up $0.09 during midday trading on Friday, hitting $81.62. The company had a trading volume of 10,657 shares, compared to its average volume of 226,211. The firm has a fifty day simple moving average of $77.34 and a two-hundred day simple moving average of $74.50. The stock has a market cap of $13.62 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 1.81 and a beta of 0.56. The company has a quick ratio of 1.92, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a fifty-two week low of $63.72 and a fifty-two week high of $84.46.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Institutional investors have recently added to or reduced their stakes in the stock. QRG Capital Management Inc. boosted its position in Dr. Reddy’s Laboratories by 2.3% in the second quarter. QRG Capital Management Inc. now owns 7,910 shares of the company’s stock valued at $603,000 after buying an additional 180 shares in the last quarter. Augustine Asset Management Inc. increased its holdings in Dr. Reddy’s Laboratories by 0.4% during the 2nd quarter. Augustine Asset Management Inc. now owns 50,624 shares of the company’s stock valued at $3,857,000 after purchasing an additional 181 shares in the last quarter. Lester Murray Antman dba SimplyRich raised its position in Dr. Reddy’s Laboratories by 3.1% in the 2nd quarter. Lester Murray Antman dba SimplyRich now owns 6,178 shares of the company’s stock valued at $470,000 after purchasing an additional 184 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in Dr. Reddy’s Laboratories by 1.6% in the first quarter. Sequoia Financial Advisors LLC now owns 14,526 shares of the company’s stock worth $1,065,000 after purchasing an additional 232 shares in the last quarter. Finally, First Trust Direct Indexing L.P. grew its holdings in shares of Dr. Reddy’s Laboratories by 2.4% during the first quarter. First Trust Direct Indexing L.P. now owns 10,634 shares of the company’s stock worth $780,000 after purchasing an additional 251 shares during the last quarter. 14.02% of the stock is owned by institutional investors and hedge funds.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.